Clinical Trial Detail

NCT ID NCT02131584
Title Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic lymphocytic leukemia

Therapies

Ruxolitinib

Age Groups: adult

No variant requirements are available.